SULFACARBAMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C7H9N3O3S
Molecular Weight	215.23
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)NS(=O)(=O)C1=CC=C(N)C=C1

InChI

InChIKey=WVAKABMNNSMCDK-UHFFFAOYSA-N

InChI=1S/C7H9N3O3S/c8-5-1-3-6(4-2-5)14(12,13)10-7(9)11/h1-4H,8H2,(H3,9,10,11)

HIDE SMILES / InChI

Molecular Formula	C7H9N3O3S
Molecular Weight	215.23
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.rlsnet.ru/mnn_index_id_677.htm
Curator's Comment: The description was created based on several sources, including https://www.drugs.com/international/sulfacarbamide.html | https://www.ncbi.nlm.nih.gov/pubmed/13154430 | http://farmaspravka.com/sulfakarbamid-sulfacarbamide | https://www.ncbi.nlm.nih.gov/pubmed/14817507

Sulfacarbamide is an antimicrobial agent that has been investigated as a therapeutic biochemical for diabetes treatment. Sulfacaramide - has a bacteriostatic effect due to competitive antagonism with PABA, preventing its inclusion in Dihydrofolic acid, which leads to a violation of the synthesis of tetrahydrofolic acid. Thus, the synthesis of nucleic acids is broken, as a result of which the growth and multiplication of microorganisms are suppressed.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
folic acid biosynthetic process 9 Target ID: GO:0046656 Sources: https://www.rlsnet.ru/mnn_index_id_677.htm	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
type 2 diabetes mellitus 5 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13633935	Primary	Not Provided 504	Sulfasalazine-EH Approved Use Unknown
Cystitis 27 Sources: https://www.rlsnet.ru/mnn_index_id_677.htm	Curative	Approved 8429	Sulfasalazine-EH Approved Use Unknown
Pyelitis 1 Sources: https://www.rlsnet.ru/mnn_index_id_677.htm	Curative	Approved 8429	Sulfasalazine-EH Approved Use Unknown
Pyelonephritis 5 Sources: https://www.rlsnet.ru/mnn_index_id_677.htm	Curative	Approved 8429	Sulfasalazine-EH Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

For adults, a single dose is 0.5-1 g 3-5 r / day. The maximum single dose is 2 g, the maximum daily intake is 7 g. The course of treatment is 6-14 days. For children, the daily dose is 1-2.5 g (in 4-5 receptions).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:13:04 UTC 2023` Edited by `admin` on `Fri Dec 15 17:13:04 UTC 2023`
Record UNII	W6CD25Z4QR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SULFACARBAMIDE

Official Name

English

UROSULFAN

Brand Name

English

Sulfacarbamide [WHO-DD]

Common Name

English

EUVERNIL

Brand Name

English

sulfacarbamide [INN]

Common Name

English

SULFAUREA

Common Name

English

URENIL

Brand Name

English

NSC-78438

Code

English

URAMID

Brand Name

English

SULFANILYLUREA [MI]

Common Name

English

SULFACARBAMIDE [MART.]

Common Name

English

4-AMINO-N-(AMINOCARBONYL)BENZENESULFONAMIDE

Systematic Name

English

SULFANILYLUREA

Systematic Name

English

URACTYL

Brand Name

English

N-SULFANILYLCARBAMIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C97936